Nephromag (Buffered Phosphate Solution | Mertiatide)

Mertiatide releases phosphate ions that act as a physiological buffer, replenishing extracellular phosphate stores, supporting cellular energy processes, bone mineralization, and helping to stabilize blood pH during intravenous therapy.

The dose of Nephromag is determined by the prescribing clinician based on the patient’s serum phosphate level, renal function, and clinical condition. Dosage regimens are individualized and not standardized.

Safety data for Nephromag in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Nephromag, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Nephromag provides a buffered phosphate formulation designed for intravenous use, offering rapid correction of phosphate deficits. Compared with non‑buffered phosphate salts, it may have a more stable pH profile, potentially reducing irritation at the infusion site, though clinical choice depends on patient needs and institutional protocols.

Nephromag should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before use, inspect for particulate matter and ensure the vial is within its expiry date.

Nephromag is administered intravenously by slow infusion, typically diluted in compatible IV fluids as directed by the prescriber. Administration rate and volume are adjusted according to the patient’s clinical status and laboratory monitoring.

Serious risks include severe hyperphosphatemia that can lead to calcium‑phosphate precipitation, anaphylactic reactions, metabolic acidosis, and worsening renal dysfunction. Continuous monitoring of serum phosphate, calcium, and renal parameters is essential during therapy.

Nephromag should be avoided in patients with known hypersensitivity to its components, uncontrolled hyperphosphatemia, severe renal failure not undergoing dialysis, or when concurrent calcium‑containing IV solutions would pose a precipitation risk.